Biotech - Spark Newswire

1 minute read

Eli Lilly-Innovent Biologics Score Expanded Use Approval of Tyvyt n Lung Cancer Patients In China

June 3, 8:18 AM

The National Medical Products Administration (NMPA) of China has approved Innovent Biologics Inc (OTC:IVBXF) and Eli Lilly And Co’s (NYSE:LLY) Tyvyt (sintilimab injection)…

IVBIY

3 minute read

Oyster Point Pharma Announces Enriched Tear Film Gene Therapy

By Bill Haddad

June 3, 8:16 AM

Oyster Point Pharma, Inc. (NASDAQ:OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, today

OYST

2 minute read

Monopar Announces New Drug Candidate, MNPR-202; Says Enters Into Collaboration Agreement With National University Of Singapore For Preclinical Evaluation In Cancer

By Benzinga Newsdesk

June 3, 8:09 AM

Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of

MNPR

1 minute read

Amryt Pharma’s Oleogel-S10 Application Gets FDA Priority Review Tag for Skin Blistering Disorder

By Vandana Singh

June 3, 8:07 AM

The FDA has granted priority review status to Amryt Pharma’s (NASDAQ:AMYT) marketing application seeking approval for Oleogel-S10 to treat Epidermolysis Bullosa (EB).…

AMYT

2 minute read

FDA
News

Hoth Therapeutics To Present Data On Preclinical Results For Its HT-KIT For mRNA Frame-Shifting On Jun. 3 at 1 p.m. EDT

By Benzinga Newsdesk

June 3, 8:06 AM

Shareholder Presentation Today to Further Highlight Results HT- KIT Reduces KIT expression and induces apoptosis of neoplastic human mast cells Inhibits tumor growth in humanized xenograft mast cell neoplasia

HOTH

1 minute read

Adaptive Biotechnologies Highlights Inclusion In Abstracts At ASCO And EHA 2021

By Bill Haddad

June 3, 7:39 AM

Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be

ADPT

6 minute read

Replimune Provides Data Update From RP1 And RP2 Programs; Co. Also Announces Plans To Expand Development Of RP2/3 Beyond Phase 1

By Bill Haddad

June 3, 7:07 AM

Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced updated interim data from the Phase 2 skin cancer cohorts

REPL

3 minute read

IGM Biosciences Highlights Expansion Of IgM Platform Into Infectious Diseases; Co. Also Highlights Publication Of Preclinical Data In Nature

By Bill Haddad

June 3, 7:06 AM

MOUNTAIN VIEW, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS) a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced

IGMS

2 minute read

FDA
News

United Therapeutics Announces First Patient Enrolled In Phase 3 TETON Study Of Tyvaso In Patients With Idiopathic Pulmonary Fibrosis

By Benzinga Newsdesk

June 3, 6:05 AM

United Therapeutics Corporation (NASDAQ:UTHR) announced today that the first patient has enrolled in the phase 3 TETON study, which is expected to evaluate approximately 396 adult patients with idiopathic pulmonary

UTHR

1 minute read

Cathie Wood Buys $6M In Intuitive Surgical, $3M In Signify Health

By Rachit Vats

June 3, 1:42 AM

Cathie Wood-led Ark Investment Management on Wednesday significantly raised its stake in Intuitive Surgical Inc (NASDAQ: ISRG) as it bought 7,259 shares of the robotic medical equipment maker, estimated to be worth about $5.96 million.

ARKG